Eli Lilly Launches New GLP-1 Weight-Loss Pill in Israel
Translated & summarized from NEWSru Israel by baba
Eli Lilly has launched its new oral GLP-1 weight-loss pill, Foundayo, in Israel, making it the fourth country to receive the drug. Available by prescription from September 15, the pill targets individuals with obesity or overweight conditions and aims for inclusion in subsidized medical services by 2027.
The story in 6 lines · by baba
- Eli Lilly's new GLP-1 weight-loss pill, Foundayo, is now available in Israel.
- Israel is the fourth country globally to receive the oral medication.
- The pill will be sold by prescription starting September 15, with prices ranging from 691 to 1146 shekels.
- The drug is intended for patients with obesity or overweight and related conditions.
- Foundayo showed a 12.4% weight reduction in trials, less than some competitors.
- The company seeks to have the drug included in Israel's subsidized medical services by 2027.
Pharmaceutical giant Eli Lilly has announced the launch of its new GLP-1 family weight-loss pill, Foundayo (Orforglipron), in the Israeli market. Israel is the fourth country globally where Lilly will offer the drug. This timing is intended to allow the company to apply for inclusion in Israel's basket of subsidized medical services by 2027.
Currently, the pill is only available through private import with a doctor's prescription and special authorization from a health maintenance organization (HMO). Foundayo will be available in pharmacies starting September 15, also by prescription only. Prices will range from 691 shekels for the lowest dosage to 1146 shekels for the highest. The extent of HMO subsidies remains undetermined.
Similar to injectable weight-loss medications, Foundayo is indicated for individuals with severe obesity or overweight conditions accompanied by at least one weight-related illness. In clinical trials, the maximum dosage of Foundayo demonstrated a 12.4% weight reduction, which is less effective than existing injectable GLP-1 drugs and also trails behind Novo Nordisk's upcoming pill, which showed a 14% to 16.6% reduction in trials.
Lilly's medication has also shown a significant decrease in the risk of death from heart disease among diabetic patients. The pill is designed for once-daily oral administration, without specific timing requirements related to meals or drinks, and does not require refrigeration.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 1Other 3
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
